Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 30770344
Zhang YS, et al. (2019) STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation. EMBO J 38 30770344
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y693-p - STAT4 (human)
Modsite: TERGDkGyVPSVFIP SwissProt Entrez-Gene
Orthologous residues
STAT4 (human): Y693‑p, STAT4 (mouse): Y694‑p, STAT4 (rat): Y693‑p
Characterization
Methods used to characterize site in vivo immunoassay, immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CD4+ (T lymphocyte), HEK293T (epithelial), IEC-6 (epithelial), spleen
Cellular systems studied:  cell lines
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase
dextran sulphate sodium LIF augment treatment-induced increase
gandotinib LIF inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation
Effect of modification (process):  cell differentiation, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
STAT4 (human) Induces co-immunoprecipitation
LIFR (human) Induces co-immunoprecipitation
STAT3 (human) Induces co-immunoprecipitation
Associated Diseases
Diseases Alterations Comments
Crohn disease increased LIF effectively inhibits Th17 accumulation and acts as a potential therapy for IBD

S713-p - STAT4 (human)
Modsite: SDSTEPHsPSDLLPM SwissProt Entrez-Gene
Orthologous residues
STAT4 (human): S713‑p, STAT4 (mouse): S714‑p, STAT4 (rat): S713‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CD4+ (T lymphocyte), HEK293T (epithelial), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited, molecular association, regulation
Effect of modification (process):  transcription, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
LIFR (human) Disrupts co-immunoprecipitation
Comments:  inhibits STAT3 activity

S721-p - STAT4 (human)
Modsite: PSDLLPMsPSVYAVL SwissProt Entrez-Gene
Orthologous residues
STAT4 (human): S721‑p, STAT4 (mouse): S722‑p, STAT4 (rat): S721‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CD4+ (T lymphocyte), HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase

S733-p - STAT4 (human)
Modsite: AVLRENLsPTTIETA SwissProt Entrez-Gene
Orthologous residues
STAT4 (human): S733‑p, STAT4 (mouse): S734‑p, STAT4 (rat): S733‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CD4+ (T lymphocyte), HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase